The makers of the lifesaving EpiPen device may have overcharged American taxpayers by as much as $1.27 billion over ten years, a U.S. senator said Wednesday.Because if you're a large pharmaceutical company, bilking everyone is part of your business model.
The Department of Health and Human Services announced the discrepancy in a letter to Sen. Chuck Grassley, claiming that the drugmaker may have conned taxpayers out of more than $1 billion by misclassifying EpiPen as a generic, rather than a brand-name drug.
A very safe prediction: Nobody will even be charged with anything. Mylan will cough up some more dough, nobody will admit to doing anything wrong, and they'll all go back to the business of trying to swindle the taxpayers and consumers.
By the way: Pharma Bro is going to trial this month and there's even a musical.
No comments:
Post a Comment